Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Operating Income: 2023-2025

Historic Operating Income for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to -$33.8 million.

  • Inhibrx Biosciences' Operating Income rose 27.75% to -$33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.0 million, marking a year-over-year increase of 58.35%. This contributed to the annual value of -$331.4 million for FY2024, which is 51.19% down from last year.
  • As of Q3 2025, Inhibrx Biosciences' Operating Income stood at -$33.8 million, which was down 23.45% from -$27.4 million recorded in Q2 2025.
  • Over the past 5 years, Inhibrx Biosciences' Operating Income peaked at -$27.4 million during Q2 2025, and registered a low of -$160.9 million during Q2 2024.
  • Over the past 3 years, Inhibrx Biosciences' median Operating Income value was -$46.3 million (recorded in 2023), while the average stood at -$61.3 million.
  • As far as peak fluctuations go, Inhibrx Biosciences' Operating Income crashed by 267.63% in 2024, and later surged by 82.98% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Operating Income (Quarterly) stood at -$88.3 million in 2023, then skyrocketed by 43.45% to -$49.9 million in 2024, then rose by 27.75% to -$33.8 million in 2025.
  • Its last three reported values are -$33.8 million in Q3 2025, -$27.4 million for Q2 2025, and -$42.9 million during Q1 2025.